The Business of Biofabrication

Teltow, February 5, 2025 – A new European initiative is set to push the boundaries of tissue regeneration and bioprinting. The micro2MACRO (m2M) project, launched in December 2024, is an EU-funded effort that aims to develop a cutting-edge bioprinting platform capable of generating personalized tissue grafts for medical applications.

The project brings together leading academic institutions, research centers, and biotech companies to create scalable, patient-specific tissue implants that can remodel into fully functional tissues after transplantation. By leveraging advanced cell aggregation and microtissue patterning, m2M seeks to enhance the effectiveness of regenerative therapies.

A Collaborative Effort in Regenerative Medicine

One of the key contributors to the project is CO.DON GmbH, a German biotech company specializing in autologous cell-based therapies. With over 30 years of experience in regenerative medicine, CO.DON has played a pioneering role in developing minimally invasive treatments for cartilage damage.

“We are proud to be a partner in the m2M project and believe in its potential to significantly advance the development of therapies for tissue regeneration,” said Dr. Giulietta Roël, Executive Director of CO.DON GmbH. “We are happy to contribute our expertise in regenerative medicine and regulatory processes, as the holder of an EU-approved cell-based therapy for cartilage repair.”

Bridging Science and Clinical Applications

Beyond the technical advancements, the m2M project is also committed to education and knowledge exchange. It plans to organize workshops and training programs to help researchers, clinicians, and healthcare professionals across Europe adopt bioprinting technologies in their work.

CO.DON’s Role in Tissue Engineering

CO.DON specializes in developing autologous cell therapies for cartilage regeneration. Its marketed product uses a patient’s own cartilage cells to repair knee joint damage through a minimally invasive approach. With over 20,000 patients treated, the company is recognized as a leader in cell-based regenerative medicine.

Following its acquisition by ReLive Biotechnologies in 2023, CO.DON continues to expand its global presence in the field of regenerative medicine. Dr. Ying Zhou, Managing Director of CO.DON, oversees the company’s strategic direction under its new ownership.

Future Implications

As the m2M project progresses, its bioprinted tissue grafts could lead to major breakthroughs in personalized medicine, reducing the reliance on traditional organ transplants and synthetic implants.

Visit this page for more info.